Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Caspofungin - Merck & Co

Drug Profile

Caspofungin - Merck & Co

Alternative Names: Cancidas; Cansidas; Caspofungin acetate; Caspofungin MSD; L 743792; L 743872; MK 0991; MK 991

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Class Antifungals; Echinocandins
  • Mechanism of Action Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Candidaemia; Candidiasis; Invasive bronchopulmonary aspergillosis; Mycoses

Most Recent Events

  • 17 Feb 2021 No development reported - Phase-II for Candidiasis (In infants, In neonates) in Bulgaria, USA, Colombia, Turkey (IV)
  • 03 Oct 2018 Efficacy and safety data from a phase II trial in Candidiasis presented at the IDWeek 2018 (IDW-2018)
  • 07 Mar 2018 Merck terminates a phase II trial in Invasive candidiasis in USA, Columbia, Bulgaria and Turkey due to operational feasibility following low recruitment due to changing epidemiology of disease (NCT01945281)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top